Outset Medical (OM) Investor presentation summary

Investment highlights

• Addresses a $2.5B acute and post-acute market, with an emerging presence in the $8.9B home market.

• More than 1,000 care sites perform over 1 million treatments annually; cumulative treatments exceed 3 million.

• Recurring revenue is ~70% of total revenue, supported by predictable utilization.

• Supported by a ~200-person sales and service organization; more than 10,000 nurses and 1,000 physicians trained.

• Strong cash position described as capitalized through breakeven.

Dialysis market and hospital burden

• U.S. ESRD care represents $71B in annual spending, including $55B paid by Medicare.

• More than 800,000 chronic dialysis patient admissions occur annually in the U.S.; hospitals lose $5,000–$25,000 per inpatient renal-failure stay with dialysis.

• Inpatient dialysis is associated with nearly 2x higher ICU admission rates, roughly 5-day longer stays and ~2.5x higher cost per stay.

• Cited operational challenges include $8.5K average loss per inpatient dialysis stay, treatment delays and nurses spending up to 40% of shifts on documentation.

Tablo solution and customer outcomes

• Tablo is designed as a single, connected and mobile dialysis device for use from bedside to ICU.

• The enterprise solution includes EMR interoperability, data analytics, fleet management, implementation services, bridge nursing and advanced support tools.

• Customer case studies reported 36% lower ICU length of stay, 75% lower CLABSI, 52% lower cost per treatment hour and over 65% lower supply and labor costs.

• Other reported customer outcomes include 35% fewer therapy start delays and over 50 nursing hours reclaimed per patient; results vary by facility and operational factors.